Vertex Pharmaceuticals price target raised to $555 from $540 at Wells Fargo

Wells Fargo raised the firm’s price target on Vertex Pharmaceuticals to $555 from $540 and keeps an Overweight rating on the shares. Updated VX-880 data presented at at ADA supports curative potential with a good safety profile, the analyst tells investors in a research note.